PHARMACEUTICAL 2024

Kiniksa Pharmaceuticals International plc
Rank 20 of 309



PHARMACEUTICAL 2024

Kiniksa Pharmaceuticals International plc
Rank 20 of 309

The relative strengths and weaknesses of Kiniksa Pharmaceuticals International plc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Kiniksa Pharmaceuticals International plc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 103% points.The greatest weakness of Kiniksa Pharmaceuticals International plc is the variable Other Expenses, reducing the Economic Capital Ratio by 4.1% points.

The company's Economic Capital Ratio, given in the ranking table, is 380%, being 166% points above the market average of 213%.

Input Variable	Value in 1000 USD
Assets, Current	276,297
Cost of Goods Sold	0
Intangible Assets	17,250
Liabilities, Current	63,666
Liabilities, Non-Current	23,817
Other Assets	232,041
Other Compr. Net Income	-38
Other Expenses	59,195
Other Liabilities	0
Other Net Income	0
Other Revenues	278,803
Property and Equipment	734
Research and Development	76,097
Selling, General and Administrative Expense	129,427

Output Variable	Value in 1000 USD
Assets	526,322
Liabilities	87,483
Expenses	264,719
Revenues	278,803
Stockholders Equity	438,839
Net Income	14,084
Comprehensive Net Income	14,065
BaseVar	578,682
ECR before LimitedLiability	316%
Economic Capital Ratio	380%